Sanoj Rejinold
Sanoj Rejinold is an Indian scientist working in South Korea.[1]
Early life and education[edit]
He is from Kannur, India. He was educated at Little Flower, Mattool, Puthiyangadi Jama-Ath High School, Kannur, and CPNS GHSS Mathamangalam until his plus-Two[definition needed]. He got a Bachelor's degree in chemistry from Payyanur College and thereafter a Master’s in chemistry (materials science) from the Kannur University Department of chemistry in 2008. After his MSc, he pursued a Ph.D. from Amrita Vishwa Vidyapeetham (2008-2014) in the area of nano drug delivery. In 2013, he received a fellowship for a joint research program called Indo-Korea Internship and was ranked first out of the 81 candidates.[2]
Career[edit]
Later, he joined as a postdoc at the Korea Advanced Institute of Science and Technology, where he spent three years of postdoc studies on anti-cancer xenograft models and a one-year research professorship in drug delivery.
In 2018, he joined as a visiting professor at Dankook University[3][not in citation given] where he worked on re-purposed oral and injectable anti-Covid formulations from 2019 to 2021 during the COVID-19 pandemic. Most of his recent works are related to COVID-19.
As of June 12, 2022, he has an H-index of 29.[citation needed] His current focus of research is triple-negative breast cancer.[4]
References[edit]
- ↑ "ORCID". orcid.org.
- ↑ "Department of Science & Technology - International Division" (PDF). Indian Institute of Technology Delhi.
- ↑ "ITREN". itren.kr.
- ↑ "SANOJ REJINOLD's Publons profile". publons.com.
This article "Sanoj Rejinold" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Sanoj Rejinold. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
